Elraglusib by Actuate Therapeutics for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval

Elraglusib is under clinical development by Actuate Therapeutics and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF).

VR Mask for PTSD Shows Promise in Decentralized Trial, Aims for FDA Breakthrough Designation

What You Should Know: – Curavit Clinical Research, a leader in decentralized clinical trials (DCTs) for digital therapeutics (DTx), successfully completed a study for the

February 15, 2024

Scientists discover critical factor in bone remodeling process

Bones are the living tissue on which the human skeleton is constructed and play a key role in enabling physical movements.

January 22, 2025

45 years of progress: Prevention and screening avert millions of cancer deaths

Research shows that cancer prevention and screening efforts prevented 5.94 million deaths across five major cancer types, highlighting their critical role.

December 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.